Theresa Rodgers, MPAS, PA-C

home / authors / theresa-rodgers-mpas-pa-c

Articles

Case Study: Sarah’s Journey with High-Burden BRAF V600E Melanoma

Michael A. Postow, MD;Evan Lipson, MD ;Hussein A. Tawbi, MD, PhD;Megan Schollenberger, MSN, CRNP;Kathleen M. Madden, MSN, FNP-BC, AOCNP®, APHN;Theresa Rodgers, MPAS, PA-C

July 18th 2025

This is an actor portrayal of a hypothetical patient profile developed for educational purposes based on characteristics of patients with multiple myeloma as seen in clinical practice. The hypothetical case was co-developed by staff medical writers with Cancer Network/ONN.

Translating RELATIVITY-020 Part E Dosing Insights to Clinical Practice

Michael A. Postow, MD;Evan Lipson, MD ;Hussein A. Tawbi, MD, PhD;Megan Schollenberger, MSN, CRNP;Kathleen M. Madden, MSN, FNP-BC, AOCNP®, APHN;Theresa Rodgers, MPAS, PA-C

July 18th 2025

Panelists discuss treatment considerations for metastatic melanoma with high tumor burden, highlighting the preference for immune checkpoint combinations like nivolumab with relatlimab for durable responses, insights from the RELATIVITY-020 trial supporting standard-dose relatlimab due to its safety and efficacy balance, and emerging LAG-3 agents such as fianlimab that may influence future therapeutic strategies.